Quest Diagnostics Incorporated
NYSE:DGXMedical - Diagnostics & Research
-$3.41 today
- Market cap
- $28.57B
- Beta
- 0.59
- P/E (TTM)
- 20.9
- EPS (TTM)
- $9.31
- Dividend yield
- 1.68%
Volume 1.30M
Average 0.91M
DGX Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Quest Diagnostics IncorporatedNYSE: DGX
Depreciation & Amortization · Q3 FY2026 · quarter ended Sep 2026
Depreciation & amortization grows in line with its trailing trend
Q3 FY2026 depreciation & amortization of $147M rose 3.5% year over year, behind the +4.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +9.3% a year.
Context
- Depreciation & amortization amounted to 5.2% of revenue in FY2025, up 0.2 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +3.5% toward the trailing-twelve-month pace of +4.5%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 570M USD
- Year-over-year change
- +15.6%
- 4-year CAGR
- +8.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 570M | +15.6% |
| FY2024 | 2024-12-31 | 493M | +12.3% |
| FY2023 | 2023-12-31 | 439M | +0.5% |
| FY2022 | 2022-12-31 | 437M | +7.1% |
| FY2021 | 2021-12-31 | 408M | — |
Depreciation & Amortization vs competitors
How DGX compares with its peers on the latest reported figures
- DGX's LTM Sep 2026 depreciation & amortization of $585M is the 2nd largest of the 9 companies compared; the peer median is $190.24M.
- Its year-over-year change of +4.5% is the 3rd highest of 9, against a peer median of -0.6%.
- Depreciation & amortization amounts to 4.9% of revenue for DGX, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $696.3M | +4.0% | +8.2% | 4.9% | |
| LTM Sep 2026 | $585M | +4.5% | +9.3% | 4.9% | |
| LTM Jul 2026 | $412.24M | -0.2% | -1.7% | 14.2% | |
| LTM Jun 2026 | $273M | -1.8% | -11.8% | 6.1% | |
| LTM Jun 2026 | $202.13M | +7.0% | -2.4% | 9.6% | |
| LTM Sep 2026 | $178.36M | -14.2% | -6.3% | 7.5% | |
| LTM Jun 2026 | $155.37M | -1.1% | +0.3% | 94.0% | |
| LTM Jun 2026 | $65.8M | +87.5% | +37.6% | 2.4% | |
| LTM Sep 2026 | $39.23M | -2.3% | +3.4% | 3.1% | |
| Peer median (excluding DGX) | $190.24M | -0.6% | -0.7% | 6.8% | |
Competitors are the stored peer set for DGX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 2.08B | 1.02B | 908M | 921M | 1.05B |
| Depreciation & Amortization | 408M | 437M | 439M | 493M | 570M |
| Deferred Income Tax | (57M) | 1M | (49M) | 13M | 105M |
| Stock-Based Compensation | 79M | 77M | 77M | 88M | 88M |
| Change in Working Capital | 87M | 119M | (145M) | (201M) | 50M |
| Accounts Receivables | 81M | 246M | (15M) | (71M) | (106M) |
| Inventory | (20M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 35M | (149M) | (55M) | (67M) | 129M |
| Other Working Capital | (9M) | 22M | (75M) | (63M) | 27M |
| Other Non-Cash Items | (364M) | 69M | 42M | 20M | 27M |
| Operating Cash Flow | 2.23B | 1.72B | 1.27B | 1.33B | 1.89B |
| Capital Expenditures | (403M) | (404M) | (408M) | (425M) | (527M) |
| Acquisitions (Net) | 424M | (144M) | (611M) | (2.16B) | (101M) |
| Purchases of Investments | (3M) | (5M) | 0 | 0 | 0 |
| Sales of Investments | 403M | 5M | 0 | 0 | 0 |
| Other Investing Activities | (400M) | 5M | (42M) | 41M | (3M) |
| Investing Cash Flow | 21M | (543M) | (1.06B) | (2.55B) | (631M) |
| Debt Repayment | (2M) | (2M) | 748M | 1.54B | (602M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 79M |
| Common Stock Repurchased | (2.2B) | (1.41B) | (275M) | (151M) | (450M) |
| Dividends Paid | (309M) | (305M) | (314M) | (331M) | (353M) |
| Other Financing Activities | (30M) | (17M) | 1M | 23M | (62M) |
| Financing Cash Flow | (2.54B) | (1.73B) | 160M | 1.08B | (1.39B) |
| Effect of Forex Changes | 0 | 0 | 0 | (7M) | 4M |
| Net Change in Cash | (286M) | (557M) | 371M | (137M) | (129M) |
| Free Cash Flow | 1.83B | 1.31B | 864M | 909M | 1.36B |
Quest Diagnostics Incorporated
NYSE:DGX
Intrinsic Alpha fair value
Locked
Current Price
$259.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.